EraGen said this week that Ronald Dunn has been appointed as vice president of quality, regulatory, and clinical affairs.
Dunn most recently served as director of global quality and regulatory with Regulatory Compliance Associates, a Kenosha, Wis.-based consulting firm. He has also held senior management positions in quality assurance at Invitrogen and Bone Care International (later acquired by Genzyme). Dunn was also a senior manager of quality assurance and regulatory compliance with Third Wave Technologies.
Fred Tenover has been appointed as senior director of scientific affairs at Cepheid, the company said recently.
Tenover, who is expected to join the company in October, will serve as a liaison with the infection control community and will lead Cepheid's healthcare-associated infection consortium program. He currently holds the position of distinguished consultant and director of the office of antimicrobial resistance at the Centers for Disease Control and Prevention. In addition, Tenover is director of the CDC/World Health Organization Collaborating Center for Global Antimicrobial Resistance Monitoring; and an adjunct professor of epidemiology at Emory University School of Public Health.